Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations

被引：1
|
作者：
Kubler, Kirsten
Nardone, Agostina
Anand, Shankara
Gorvich, Daniel
Droog, Marjolein
Hermida-Prado, Francisco
Akshi, Tara
Feit, Avery S.
Cohen, Gabriella
Dackus, Gwen
Pun, Matthew
Kuang, Yanan
Cha, Justin
Miller, Mendy
Gibson, William J.
Paweletz, Cloud P.
Van Allen, Eliezer M.
van Leeuwen, Flora E.
Nederlof, Petra
Hollema, Harry
Quang-De Nguyen
Mourits, Marian J. E.
Leshchiner, Ignaty
Stewart, Chip
Matulonis, Ursula A.
Zwart, Wilbert
Maruvka, Yosef E.
Getz, Gad
Jeselsohn, Rinath
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-GS2-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS2-09
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers
    Payne, Susan
    Depke, Mitchell
    Yueh, Alex
    Sharick, Joseph T.
    Favreau, Peter F.
    Pasch, Cheri A.
    Clipson, Linda
    Matkowskyj, Kristina A.
    Skala, Melissa
    Deming, Dustin A.
    CANCER RESEARCH, 2018, 78 (13)
  • [32] PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway
    Hu, Huayu
    Zhu, Junyong
    Zhong, Yuting
    Geng, Rui
    Ji, Yashuang
    Guan, Qingyu
    Hong, Chenyan
    Wei, Yufan
    Min, Ningning
    Qi, Aiying
    Zhang, Yanjun
    Li, Xiru
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (05)
  • [33] Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers
    Fang, Wen-Liang
    Huang, Kuo-Hung
    Lan, Yuan-Tzu
    Lin, Chien-Hsing
    Chang, Shih-Ching
    Chen, Ming-Huang
    Chao, Yee
    Lin, Wen-Chang
    Lo, Su-Shun
    Li, Anna Fen-Yau
    Wu, Chew-Wun
    Chiou, Shih-Hwa
    Shyr, Yi-Ming
    ONCOTARGET, 2016, 7 (05) : 6201 - 6220
  • [34] Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3K alpha specific inhibitors and ATP
    Mentes, Muratcan
    Karakuzulu, Basak Buse
    Ucar, Gonlum Bahar
    Yandim, Cihangir
    COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2022, 99
  • [35] Targeting PI3K/AKT Pathway is an Effective Strategy for the Treatment of Neuroendocrine Tumors Harboring PIK3CA Mutations
    Song, Jun
    Li, Jing
    Kim, Ji Tae
    Weiss, Heidi
    Townsend, Courtney M.
    Evers, B. N.
    GASTROENTEROLOGY, 2011, 140 (05) : S116 - S117
  • [36] Activating PIK3CA mutations and hedgehog signaling may confer resistance to KRAS inhibition in colorectal cancer
    Chowdhury, Saikat
    Ahmed, Jibran
    Haridas, Valsala
    Hong, David S.
    Kopetz, Scott
    Shen, John Paul
    CANCER RESEARCH, 2024, 84 (06)
  • [37] Mutational status of PIK3ca oncogene in oral cancer-In the new age of PI3K inhibitors
    Denninghoff, V
    Muino, A.
    Diaz, M.
    Harada, L.
    Lence, A.
    Turon, P.
    Labbrozzi, M.
    Aguas, S.
    Penaloza, P.
    Avagnina, A.
    Adler, I
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (01)
  • [38] CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
    Vora, Sadhna R.
    Juric, Dejan
    Kim, Nayoon
    Mino-Kenudson, Mari
    Huynh, Tiffany
    Costa, Carlotta
    Lockerman, Elizabeth L.
    Pollack, Sarah F.
    Liu, Manway
    Li, Xiaoyan
    Lehar, Joseph
    Wiesmann, Marion
    Wartmann, Markus
    Chen, Yan
    Cao, Z. Alexander
    Pinzon-Ortiz, Maria
    Kim, Sunkyu
    Schlegel, Robert
    Huang, Alan
    Engelman, Jeffrey A.
    CANCER CELL, 2014, 26 (01) : 136 - 149
  • [39] PIK3CA mutations in ovarian cancer -: Response
    Levine, DA
    Boyd, J
    CLINICAL CANCER RESEARCH, 2005, 11 (19) : 7042 - 7043
  • [40] Aspirin and PIK3CA Mutations in Colorectal Cancer
    Kirstein, M. M.
    Vogel, A.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2014, 52 (03): : 306 - 307
12345